Clinical trials
Cholangiocarcinoma clinical trials
Below are recruiting cholangiocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 190 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06440993RecruitingPhase 2
Durvalumab with bile duct heat therapy for bile duct cancer
This trial tests a combination of a drug (durvalumab) that helps your immune system fight cancer, plus a special heat treatment applied inside the bile duct. It is for people with bile duct cancer that cannot be removed by surgery and who need a stent to open the bile duct.
AachenAges 18 years+ - NCT06439485RecruitingPhase 1/Phase 2
Combination drug therapy for advanced bile duct cancer with FGFR2 change
This trial tests a combination of three drugs (pemigatinib, atezolizumab, and bevacizumab) for people with advanced bile duct cancer that has a specific genetic change called FGFR2 fusion. The goal is to see if this combination can shrink or control the cancer when standard treatments have stopped working.
Houston, TexasAges 18 years+ - NCT06416397Recruiting
Bile test for bile duct cancer diagnosis
This trial tests whether a sample of bile (a fluid produced by your liver) can help doctors diagnose bile duct cancer more accurately. If you have a narrowing in your bile duct and need a procedure to take a tissue sample, you may be able to participate.
PessacAges 18 years+ - NCT06375915RecruitingPhase 2
Radioembolization and targeted therapy for unresectable bile duct cancer
This trial combines a liver-directed radiation therapy (radioembolization) with a targeted drug to treat a specific type of bile duct cancer that cannot be surgically removed. The goal is to see if this combination can shrink the tumor and improve outcomes.
BergamoAges 18–80 - NCT06342414Recruiting
Blood test to tell apart two types of liver cancer
This study uses a blood test (called a liquid biopsy) to help doctors tell the difference between two common types of liver cancer: hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). If you have been diagnosed with one of these cancers and have a blood sample taken before starting curative treatment, this study may help improve diagnosis and care.
Duarte, CaliforniaAges 18 years+ - NCT06313203RecruitingPhase 2
Chemotherapy with or without liver-directed treatment for bile duct cancer
This trial tests whether adding a liver-directed treatment (HAI floxuridine or SIRT) to standard chemotherapy (GemOx) is more effective for people with bile duct cancer inside the liver that cannot be removed by surgery. It may be an option for those whose cancer is only in the liver or nearby lymph nodes.
Oslo, OsloAges 18 years+ - NCT06192797RecruitingPhase 2
Combination therapy for unresectable bile duct cancer
This trial tests a combination of three treatments—a liver-directed chemotherapy infusion (HAIC), a targeted therapy pill (lenvatinib), and an immunotherapy (pucotenlimab)—to try to shrink bile duct cancers that cannot be surgically removed. The goal is to make the cancer surgically removable or to control it for as long as possible.
Wuhan, HubeiAges 18 years+ - NCT06175845Recruiting
Endoscopic radiofrequency ablation for bile duct cancer
This trial tests a minimally invasive treatment using heat (radiofrequency ablation) to destroy cancer cells in the bile duct. It's for patients whose bile duct cancer cannot be removed by surgery and who are also receiving systemic therapy.
BerlinAges 18 years+ - NCT06125769Recruiting
Liver transplant for hard-to-treat bile duct cancer
This trial studies liver transplantation to treat a specific bile duct cancer (perihilar cholangiocarcinoma) that cannot be removed by surgery. It aims to see if a transplant can help when standard chemotherapy has kept the cancer stable.
Padova, PADOVAAges 18–70 - NCT06101277Recruiting
Local therapy for limited new cancer growth in digestive cancers
This trial tests a cancer treatment that uses local therapies (like radiation or targeted heat) to destroy a small number of growing spots. It is for people with certain gastrointestinal cancers whose main treatment is working well except for a few new spots, so they can avoid switching to a different drug right away.
Sacramento, CaliforniaAges 18 years+ - NCT05967182RecruitingPhase 2
Pembrolizumab plus chemo before or around liver surgery
This trial tests whether pembrolizumab combined with gemcitabine and cisplatin given around the time of surgery can improve outcomes for people with high-risk, potentially operable intrahepatic cholangiocarcinoma (bile duct cancer in the liver). It may help by strengthening the immune system while also treating the cancer with chemotherapy.
Houston, TexasAges 18 years+ - NCT05874414RecruitingPhase 1/Phase 2
Combination therapy for advanced KRAS-mutated bile duct cancer
This trial tests a new combination of two drugs, GNS561 and trametinib, for people with advanced bile duct cancer (cholangiocarcinoma) that has a specific genetic change called a KRAS mutation. The goal is to see if this combination can shrink tumors or slow the disease after prior chemotherapy.
Los Angeles, CaliforniaAges 18 years+ - NCT05727176RecruitingPhase 2
Futibatinib for advanced bile duct cancer with FGFR2 changes
This trial tests futibatinib, a targeted pill, in people with advanced (unresectable) or metastatic bile duct cancer that has an FGFR2 fusion or rearrangement. It may help shrink tumors after standard chemotherapy has stopped working.
La Jolla, CaliforniaAges 18 years+ - NCT05568680RecruitingPhase 1
Early trial of SynKIR-110 for certain ovarian and lung-lining cancers
This Phase 1 study tests SynKIR-110 in people with certain advanced cancers that have come back or continued growing after prior treatments. It aims to find out if the treatment is safe and how the body responds, including early signs of effectiveness.
Tampa, FloridaAges 18 years+ - NCT05546372Recruiting
Radiofrequency ablation to treat blocked bile ducts from bile cancer
This study tests whether radiofrequency ablation can improve treatment for people who have a malignant (cancer-related) blockage of the bile ducts near the liver (perihilar cholangiocarcinoma). It’s for patients who are not good candidates for curative surgery and who need bile-duct drainage using a specific stent (uSEMS).
AmsterdamAges 18 years+ - NCT05430698RecruitingPhase 2
PD-1 antibody after surgery for bile duct cancer
This Phase 2 trial studies whether adding a PD-1 antibody plus gemcitabine/oxaliplatin (GEMOX) after surgery can lower the chance of the cancer coming back in perihilar cholangiocarcinoma. It’s for people who have had surgery with no tumor left at the cut edges, but lymph nodes showed cancer under the microscope.
Guangzhou, GuangdongAges 18–75 - NCT05404503Enrolling by invitation
Check how often bile-duct cancer happens in choledochal cysts
This study looks at how frequently cholangiocarcinoma (bile-duct cancer) occurs in people with choledochal cysts (a swelling of bile ducts). It mainly uses existing imaging records to understand risk in a hospital population.
HuelvaAges Any age - NCT05285358RecruitingPhase 1
Aerosol chemo plus standard drugs for bile duct and gallbladder cancer
This trial tests a new way to give the drug paclitaxel directly into your belly as a mist, along with two standard chemo drugs given through your veins, for bile duct or gallbladder cancer that has spread to the lining of the belly. The goal is to see if this approach can better control the cancer in the belly.
Duarte, CaliforniaAges 18 years+ - NCT04353375RecruitingPhase 2/Phase 3
Study drug for FGFR2-mutated bile duct cancer
This trial tests HMPL-453 to treat advanced intrahepatic cholangiocarcinoma (bile duct cancer) that has an FGFR2 change. It may help shrink tumors or control the disease in people whose cancer has not responded well to prior treatment.
Beijing, Beijing MunicipalityAges 18 years+ - NCT03364530RecruitingPhase 2
Liver artery chemotherapy for non-surgical bile duct cancer
This trial tests delivering two chemotherapy medicines directly into the liver’s artery in people with bile duct cancer inside the liver that cannot be removed with curative surgery. It aims to control the cancer after first-line treatment and see how well this targeted approach works.
AmiensAges 18 years+ - NCT04891289RecruitingPhase 2
Gemcitabine and oxaliplatin with a chemotherapy pump for bile duct cancer
This Phase 2 study tests gemcitabine plus oxaliplatin chemotherapy, and whether adding a chemotherapy pump (with floxuridine and dexamethasone) delivered to the liver improves outcomes. It is for people whose intrahepatic cholangiocarcinoma cannot be removed with surgery.
Bethesda, MarylandAges 18 years+ - NCT04378023Recruiting
Liver transplant plus chemo-radiation for bile duct cancer
This study tests giving chemo and radiation before a liver transplant for an unresectable bile duct cancer near the liver (hCCA). If your cancer can’t be removed with surgery right now, this approach aims to shrink and control it so transplant may become an option.
Barcelona, BarcelonaAges 18–70 - NCT04195503Enrolling by invitation
Liver transplant for stable advanced bile duct cancer
This trial looks at liver transplant for people with advanced intrahepatic cholangiocarcinoma (a bile duct cancer inside the liver) when the cancer is not safely removable and stays controlled. It may help some patients live longer and with better quality of life by replacing the diseased liver—if strict safety and disease-stability requirements are met.
Toronto, OntarioAges 18 years+ - NCT04792463Recruiting
BAP1 gene cancer-risk study and family cancer patterns
This study looks at how the BAP1 gene affects cancer risk and what cancers people develop, including within families. You may be able to join if you have a known BAP1-related mutation, a strong family cancer history, or a concerning cancer pattern linked to BAP1.
Columbus, OhioAges Any age
Hear when a new Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cholangiocarcinoma?
- Yes. Clin2 currently lists 190 recruiting cholangiocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cholangiocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cholangiocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.